Date: 2015-10-28
Type of information: Collaboration agreement
Compound: research grade and clinical grade laminins for ex vivo cell culture applications
Company: CEVEC Pharmaceuticals (Germany) Biolamina (Sweden)
Therapeutic area: Technology - Services
Type agreement: collaboration production manufacturing
Action mechanism: protein. Laminins are human recombinant proteins used to solve technical problems within the culturing of embryonic stem cells and other types of primary cells. These proteins provide these cells a natural environment when they are first used to coat the plastic cell culture dishes. Many different types of cells thrive on these laminins because these same proteins surround different types of cells also in the human body.
Disease:
Details: * On October 28, 2015, Cevec Pharmaceuticals, a producer of tailor-made recombinant glycoproteins and gene therapy vectors, and BioLamina, amanufacturer of high quality products for primary cell culture, announced a strategic collaboration for the commercial production of research grade and clinical grade laminins for ex vivo cell culture applications using Cevec’s proprietary CAP®Go technology. Under the terms of the agreement, Cevec will provide its expertise in process development as well as its competence in GMP production, in collaboration with its joint venture partner GenIbet, of selected laminins based on the Company’s proprietary CAP®Go technology. This joined competence embraces cell line and process development, GMP cell banking and GMP production including fill & finish. Cevec retains the rights to develop laminins for therapeutic use and grants BioLamina an exclusive license for the commercialization of CAP®Go based laminins patented by BioLamina for ex vivo cell culture therapies. The first laminin, Laminin-521, which is used to proliferate stem cells without causing genomic abnormalities, will be launched in 2016. BioLamina focuses on research and development, to understand how laminins can be used to deplete technical problems associated in primary cell culture as well as on global sales and marketing of the commercially produced and finished products through its direct sales force and network of distributors. In this long-term strategic cooperation, BioLamina plans to initially add up to six new variants of laminins to its leading portfolio of recombinant laminins to enable cell culture of an accelerating range of human cell types with increased reliability and quality.
Financial terms: Financial details of this agreement were not disclosed.
Latest news:
